Results 91 to 100 of about 767,969 (287)
Luck or Skill? An Examination of the Ehrlich - Simon Bet [PDF]
In 1980, Paul Ehrlich and Julian Simon placed a famous bet on whether the prices of a bundle of natural resources would rise or fall over the ensuing decade. Simon won the bet as the real price of the bundle fell significantly, and the result of this bet
Kevin Golembiewski +2 more
core
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
, 2017 The chemopreventive and anticancer effects of resveratrol (RSV) are widely reported in the literature. Specifically, mechanisms involving epigenetic regulation are promising targets to regulate tumor development. Bromodomains act as epigenetic readers by
Knapp, Stefan +18 more
core +1 more source
Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization
Molecular Oncology, EarlyView.In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu +13 more
wiley +1 more source
BET isoform selectivity through diverse linkers for bivalent inhibitors : GSK785, a BRD2/4-selective bivalent BET inhibitor [PDF]
The inhibition of the Bromodomain and Extra Terminal (BET) family of proteins has been widely studied for over a decade for its potential therapeutic benefit in cancer and immuno-inflammatory diseases.
Grandi, Paola +12 more
core +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma
Neoplasia: An International Journal for Oncology Research, 2019 Studies on the efficacy of small molecule inhibitors in Merkel cell carcinoma (MCC) have been limited and largely inconclusive. In this study, we investigated the therapeutic potential of a potent BET degrader, BETd-246, in the treatment of MCC. We found
Jae Eun Choi +20 more
doaj +1 more source
I-BET-762 treatment suppresses AHR and inflammatory cells after IFNγ/LPS stimulation.
, 2016 Mice were administered IFNγ/LPS i.t at 0h. Some mice were treated with I-BET-762 or vehicle (hydroxyl-β cyclodextrin) i.v 1h before and 4h after IFNγ/LPS exposure. Endpoints were assessed at 12h.
Ming Yang (109148) +4 more
core +1 more source
ING4 (inhibitor of growth family, member 4) [PDF]
, 2011 Review on ING4 (inhibitor of growth family, member 4), with data on DNA, on the protein encoded, and where the gene is ...
Miranda, C, Greco, A
core +1 more source
Molecular Oncology, EarlyView.Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source